

Primerdesign Ltd

# SNPsig<sup>®</sup> SARS-CoV-2 (EscapePLEX)

**Identification of clinically significant mutations  
E484K, K417N, K417T and P681R**

SNPsig<sup>®</sup> Real-Time PCR  
SARS-CoV-2 mutation detection/allelic  
discrimination kit

96 tests

For general laboratory and research use only

Kits by Primerdesign

## Kit contents

- **SARS-CoV-2 EscapePLEX genotyping primer/probe mix tube 1 (96 reactions **BROWN**)**  
FAM, HEX/VIC, ROX and Cy5 labelled
- **SARS-CoV-2 EscapePLEX genotyping primer/probe mix tube 2 (96 reactions **BROWN**)**  
FAM, HEX/VIC and ROX labelled
- **Positive control templates tube 1 (**RED**)**
- **Positive control templates tube 2 (**RED**)**
- **Internal control RNA (**BLUE**)**
- **RNase/DNase free water (**WHITE**)**  
for resuspension of primer/probe mix
- **2 tubes of template preparation buffer (**YELLOW**)**  
for resuspension of positive control templates
- **4 vials of Onestep Lyophilised Master Mix (**GOLD**)**  
contains complete Onestep RT-qPCR Master Mix
- **4 tubes of Master Mix resuspension buffer (**BLUE**)**  
for resuspension of the lyophilised Master Mix

## Reagents and equipment to be supplied by the user

### Real-Time PCR Instrument

Must be able to read fluorescence through FAM, HEX/VIC, ROX and Cy5 channels

### Pipettes and Tips

### Vortex

### Centrifuge

Suitable Real-Time PCR 96W plates or Real-Time PCR reaction tubes

## Kit storage and stability

This kit is stable at room temperature but should be stored at -20°C on arrival. Primerdesign does not recommend using the kit after the expiry date stated on the pack. Once the lyophilised components have been resuspended, unnecessary repeated freeze/thawing should be avoided. The kit is stable for six months from the date of resuspension under these circumstances.

## Suitable sample material

SNPsig® SARS-CoV-2 (EscapePLEX) is intended for use as a reflex test only. Thus, a primary confirmation test for SARS-CoV-2 would be carried out using suitable methodology, and the extracted RNA from patient samples (or any material suited for PCR amplification) thereafter applied to this test. Please ensure that the samples are suitable in terms of purity, concentration, and RNA integrity. Always run at least one negative control with the samples. To prepare a negative control, replace the template RNA sample with RNase/DNase free water.

## Notices and disclaimers

This product is developed, designed, and sold for research purposes only. It is not intended for human diagnostic or drug purposes or to be administered to humans unless clearly expressed for that purpose by the Food and Drug Administration in the USA or the appropriate regulatory authorities in the country of use. During the warranty period Primerdesign SNPsig® detection kits allow precise and reproducible data recovery combined with excellent sensitivity. For data obtained by violation to the general GLP guidelines and the manufacturer's recommendations the right to claim under guarantee is expired. PCR is a proprietary technology covered by several US and foreign patents. These patents are owned by Roche Molecular Systems Inc. and have been sub-licensed by PE Corporation in certain fields. Depending on your specific application you may need a license from Roche or PE to practice PCR. Additional information on purchasing licenses to practice the PCR process may be obtained by contacting the Director of Licensing at Roche Molecular Systems, 1145 Atlantic Avenue, Alameda, CA 94501 or Applied Biosystems business group of the Applied Biosystems Corporation, 850 Lincoln Centre Drive, Foster City, CA 94404. In addition, the 5' nuclease assay and other homogeneous amplification methods used in connection with the PCR process may be covered by U.S. Patents 5,210,015 and 5,487,972, owned by Roche Molecular Systems, Inc, and by U.S. Patent 5,538,848, owned by The Perkin-Elmer Corporation.

## Trademarks

Primerdesign™ is a trademark of Primerdesign Ltd.

The PCR process is covered by US Patents 4,683,195, and 4,683,202 and foreign equivalents owned by Hoffmann-La Roche AG. BI, ABI PRISM® GeneAmp® and MicroAmp® are registered trademarks of the Applied Biosystems (Applied Biosystems Corporation).

BIOMEK® is a registered trademark of Beckman Instruments, Inc.; iCycler™ is a registered trademark of Bio- Rad Laboratories, Rotor-Gene is a trademark of Corbett Research.

LightCycler™ is a registered trademark of the Idaho Technology Inc. GeneAmp®, TaqMan® and AmpliTaqGold® are registered trademarks of Roche Molecular Systems, Inc., The purchase of the Primerdesign reagents cannot be construed as an authorization or implicit license to practice PCR under any patents held by Hoffmann-La Roche Inc.

# Introduction

The novel coronavirus disease 2019 (COVID-19) pandemic, caused by SARS-CoV-2 virus, represents a major threat to health. SARS-CoV-2 has resulted in widespread morbidity and mortality. COVID-19 is known to have infected more than 100 million people (1). As the virus has spread across the world, mutations have arisen resulting in divergent clusters (clades) with different prevalence in different geographic regions (2,3).

Since the beginning of the pandemic, governments and scientists have applied sequencing technologies to identify mutations which modify the characteristics of the SARS-CoV-2, including mutations which alter transmissibility (4) or that are associated with a reduced affinity for key neutralising antibodies (5-7). These mutations mostly occur within the spike protein and are predicted to alter the way that SARS-CoV-2 interacts with Angiotensin I converting enzyme 2 (ACE2) receptor.

Recently, four clinically significant mutations have been identified as “high risk” due to the concerning increase in numbers of active cases carrying them.

E484K has been detected in a wide variety of Variants of Concern (VOC) and Variants Under Investigation (VUI), including Beta (B.1.351) Gamma (P.1), VOC-21FEB-02 (Alpha (B.1.1.7) with E484K), Zeta (P.2) and Theta (P.3) (8-11). Multiple studies on E484K have associated this change in amino acid with the ability to evade antibodies (12-14), increase disease severity and its potential impact on vaccines (15-18) with enormous implications for public health approaches in combatting COVID-19 cases.

The site K417 in the spike protein corresponds with an area in the protein that is considered a hotspot for antibody recognition (19). Therefore, changes in this position would have a potential role in antibody and vaccine escape. At present, two mutations on this site have been recognised and associated with reduced antibody protection. K417T was firstly identified in the VOC P.1 (20) and K417N was firstly identified as part of the VOC Beta (3.1.351) (19-20). In addition, K417N has been demonstrated to provide the virus with a moderate increase in transmissibility rates due to the very specific change induced by the K to N amino acid replacement (21).

P681R has been found in the recently identified VOC and VUI Kappa (B.1.617.1), Delta (B.1.617.2) and B.1.617.3 related variants (22). This mutation has been associated with a potential increase in transmissibility rate based on mechanistic studies on the capacity of the virus to identify and infect human cells (22).

Identifying variants that carry any of these four mutations in a timely manner may be important for making public health decisions. The product will be developed in a standard SNPsig format. It will enable the identification of these mutations (E484K, K417N/T and P681R) on previously identified SARS-CoV-2 positive samples.

# Principles of the test

## Genotyping by Real-Time PCR using hydrolysis probes

Each genotyping primers/probe mix contain four (tube 1) and three (tube 2) labelled probes homologous to the genotypes under investigation and the Internal Control. The SNPsig® assays are compatible with all Real-Time PCR instruments capable of detecting fluorescence in FAM, HEX/VIC, ROX and Cy5 emission channels, including selected genesig® family instruments.

Reagent Label	FAM	HEX/VIC	ROX	Cy5
SNPsig® SARS-CoV-2 (EscapePLEX) Tube 1	E484K	K417N	K417T	P681R
SNPsig® SARS-CoV-2 (EscapePLEX) Tube 2	Orf1ab region	Internal Control	M region	N/A

## Positive control Template

The kit contains two positive control templates tubes. Tube 1 contains the four synthetic templates homologous to the clinically significant mutations E484K, K417N, K417N and P681R. Tube 2 contains synthetic templates homologous to the Orf1ab and M gene target regions. These should be run with the appropriate primer/probe tube to obtain control signals for each target. Positive control templates are a potential contamination risk to subsequent tests so must be handled carefully.

## Negative control

To confirm the absence of contamination a negative control reaction should be included for each primer/probe tube, every time the kit is used. In this instance, the RNase/DNase free water should be used instead of template RNA. A negative result in FAM, HEX/VIC, ROX and Cy5 channels indicates that the reagents have not become contaminated while setting up the run. If a positive result is obtained, this indicates contamination, therefore the sample results will be invalid, and the run should be repeated.

Possible sources of contamination should first be explored and removed.

## Master mix compatibility

Onestep Lyophilised Master Mix contains the enzyme, nucleotides, buffers, and salts at precisely the correct concentration for this application. The annealing temperatures of the primers and probes have been carefully calibrated and any change in the reaction buffer can significantly alter the performance of the assay. For this reason, Primerdesign can only guarantee accurate genotyping results when Onestep Lyophilised Master Mix is used.

# Resuspension Protocol

To minimize the risk of contamination with foreign RNA/DNA, we recommend that all pipetting be performed in a PCR clean environment. Ideally this would be a designated PCR lab or PCR cabinet. Filter tips are recommended for all pipetting steps. The positive control template is a significant contamination risk and should therefore be pipetted after negative control and sample wells.

## 1. Pulse-spin each tube in a centrifuge before opening.

This will ensure that the lyophilised primer/probe mix is in the base of the tube and is not lost upon opening the tube.

## 2. Resuspend the primer/probe mix in the RNase/DNase free water supplied, according to the table below.

To ensure complete resuspension, vortex the tube thoroughly.

Component - Resuspend in water	Volume
SARS-CoV-2 ( <b>EscapePLEX</b> ) genotyping primer/probe mix <b>tube 1</b> (BROWN)	110 µl
SARS-CoV-2 ( <b>EscapePLEX</b> ) genotyping primer/probe mix <b>tube 2</b> (BROWN)	110 µl

## 3. Resuspend the Master Mix in Resuspension Buffer supplied, according to the table below.

Component - Resuspend in Resuspension Buffer	Volume
Onestep Lyophilised Master Mix ( <b>GOLD</b> )	525 µl

## 4. Resuspend the Positive Control Templates tube in the Template Preparation Buffer supplied, according to the table below.

To ensure complete resuspension, vortex each tube thoroughly.

Component - Resuspend in Template Preparation Buffer	Volume
Positive Control Template tube 1 ( <b>RED</b> ) *	500 µl
Positive Control Template tube 2 ( <b>RED</b> ) *	500 µl

\* This component contains high copy number template and is a VERY significant contamination risk. It must be opened and handled in a separate laboratory environment, away from the other components.

## 5. Resuspend the Internal Control Templates tube in the Template Preparation Buffer supplied, according to the table below.

Component - Resuspend in Template Preparation Buffer	Volume
Internal Control Template ( <b>BLUE</b> )	500 µl

# Real-Time PCR detection protocol

1. Prepare 2 reaction mixes, one for each primers/probes mix.
2. Include sufficient reactions for all samples, positive and negative controls.

## Reaction mix for Tube 1:

Component	Volume
Onestep Lyophilised Master Mix	10 µl
SARS-CoV-2 ( <b>EscapePLEX</b> ) genotyping primer/probe mix Tube 1	1 µl
RNase/DNase free water (WHITE)	4 µl
<b>Final Volume</b>	<b>15 µl</b>

## Reaction mix for Tube 2:

Component	Volume
Onestep Lyophilised Master Mix	10 µl
SARS-CoV-2 ( <b>EscapePLEX</b> ) genotyping primer/probe mix Tube 2	1 µl
Internal Control	1 µl
RNase/DNase free water (WHITE)	3 µl
<b>Final Volume</b>	<b>15 µl</b>

3. Pipette 15 µl of the appropriate reaction mix into each well according to your Real-Time PCR experimental plate set up, to enable each sample to be tested with each reaction mix.
4. Prepare RNA templates for each of your samples.  
  
As this is a reflex test, the RNA obtained from the confirmatory primary assay for SARS- CoV-2 will be used.
5. Pipette 5 µl of RNA template into each well, according to your experimental plate set up.
6. For negative control wells use 5 µl of RNase/DNase free water.
7. Pipette 5 µl of each positive control RNA according to your experimental plate set-up. The final volume in each well is 20 µl.

# Real-Time PCR amplification protocol

The following protocol is recommended for optimum resolution between genotypes:

Protocol for Onestep Lyophilised Master Mix

	Step	Time	Temp
	Reverse transcription	10 min	55 °C
	Enzyme activation	2 min	95 °C
Cycling x45	Denaturation	10 s	95 °C
	Annealing and extension*	60 s	60 °C

\* Fluorogenic data should be collected during this step through the **FAM, HEX/VIC, ROX** and **Cy5** channels for tube 1 and **FAM, HEX/VIC** and **ROX** for tube 2.

# Interpretation of results

The SNPsig® SARS-CoV-2 (EscapePLEX) allows simultaneous discriminatory identification of the four clinically significant mutations, E484K, K417N, K417T and P681R in tube 1. Tube 2 allows the confirmation of a SARS-CoV-2 positive sample.

Positive control templates are expected to amplify between Cq 16 and 23. Failure to satisfy this quality control criterion is a strong indication that the experiment has been compromised.

The negative controls should be free from amplification in all channels, except for IC amplification in Tube 2.

## Sample Interpretation:

### In tube 1:

- E484K should produce a fluorescence signal on FAM channel.
- K417N should produce a fluorescence signal on HEX/VIC channel.
- K417T should produce a fluorescence signal on ROX channel.
- P681R should produce a fluorescence signal on Cy5 channel (see table below).

FAM (E484K)	HEX/VIC (K417N)	ROX (K417T)	Cy5 (P681R)	Results
+	-	-	-	Positive for E484K
+	+	-	-	Positive for E484K + K417N
-	+	-	-	Positive for K417N
-	-	+	-	Positive for K417T
+	-	+	-	Positive for E484K + K417T
-	-	-	+	Positive for P681R
-	+	-	+	Positive for P681R + K417N

Lack of fluorescence in a channel could either indicate a sample with Wild-type sequence at that site or a sample with a different mutation at the target site. Combination of mutations (+ in more than one channel) is possible. For any additional fluorescence profiles, we suggest sending the sample for sequencing.

Due to the evolution of new variants and the extinction of others, the variants associated with the mutation profiles in the above table have not been added. For the latest information on currently circulating SARS-CoV-2 variant please see:

Investigation of SARS-CoV-2 variants of concern: technical briefings - GOV.UK ([www.gov.uk](http://www.gov.uk))

Tracking SARS-CoV-2 variants ([who.int](http://who.int))

The mutation profiles of these variants and other circulating clades can be found at: [outbreak.info](http://outbreak.info)

**In tube 2:**

- Orf1ab region should produce a fluorescence signal on FAM channel.
- IC should produce a fluorescence signal on HEX/VIC channel.
- M region should produce a fluorescence signal on ROX channel (see table below).

FAM (Orf1a region)	HEX/VIC (IC)	ROX (M region)	Cy5	Results
+	+	+	N/A	SARS-CoV-2 Positive
+	+	-	N/A	SARS-CoV-2 Positive
-	+	+	N/A	SARS-CoV-2 Positive
-	+	-	N/A	SARS-CoV-2 Negative

# References

1. World Health Organisation (WHO). Coronavirus disease (COVID-19) [Internet]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
2. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. NextStrain: Real-time tracking of pathogen evolution. *Bioinformatics* [Internet]. 2018; 34(23):4121–3. Available from: <https://pubmed.ncbi.nlm.nih.gov/29790939/>
3. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2 [Internet]. [cited 2021 Jan 13]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/>
4. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. *Cell* [Internet]. 2020;182(5):1295-1310.e20. Available from: <http://dx.doi.org/10.1016/j.cell.2020.08.012>
5. Rees-Spear C, Muir L, Griffith SA, Heaney J, Aldon Y, Snitselaar JL, et al. The impact of Spike mutations on SARS-CoV-2 neutralization. *bioRxiv* 2021. Available from: <https://doi.org/10.1101/2021.01.15.426849>
6. Hendy M, Kaufman S, Ponga M. Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations. *bioRxiv* 2021. Available from: <https://doi.org/10.1101/2021.03.04.433970>.
7. Gupta RK. Will SARS-CoV-2 variants of concern affect the promise of vaccines? [published online ahead of print, 2021 Apr 29]. *Nat Rev Immunol*. 2021;1-2. doi:10.1038/s41577-021-00556-5
8. Public Health England. PHE statement on Variant of Concern and new Variant Under Investigation [Internet]. UK Government. 2021. Available from: <https://www.gov.uk/government/news/phe-statement-on-variant-of-concern-and-new-variant-under-investigation>
9. Gröhs Ferrareze PA, Bonetti Franceschi V, de Menezes Mayer A, Dickin Caldana G, Zimmerman RA, Thompson CA. E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. *bioRxiv* 2021. Available from: <https://doi.org/10.1101/2021.01.27.426895>.
10. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. *medRxiv* [Internet]. 2020; Available from: <https://doi.org/10.1101/2020.12.21.20248640>
11. Bascos NAD, Mirano-Bascos D, Saloma CP. Structural Analysis of Spike Protein Mutations in the SARS-CoV-2 P.3 Variant. *bioRxiv* 2021. Available from: <https://doi.org/10.1101/2021.03.06.434059>
12. Andreano E, Piccini G, Licastro D, Casalino L, Johnson N V, Paciello I, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. *bioRxiv* [Internet]. 2020;2020.12.28.424451. Available from: <http://biorxiv.org/content/early/2020/12/28/2020.12.28.424451.abstract>
13. Greaney AJ, Loes AN, Crawford KH, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. [cited 2021 Jan 19]; Available from: <https://doi.org/10.1101/2020.12.31.425021>
14. Cele S, Gazy I, Jackson L, Hwa S-H, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. *medRxiv* [Internet]. 2021 [cited 2021 Jan 25];1–19. Available from: <https://www.medrxiv.org/content/10.1101/2021.01.26.21250224v1>
15. Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. *bioRxiv* [Internet]. 2021 [cited 2021 Jan 29]; Available from: <https://doi.org/10.1101/2021.01.25.427948>
16. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Fink S, Schaefer-Babajew D, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *bioRxiv* [Internet]. 2021 [cited 2021 Jan 25]; Available from: <https://doi.org/10.1101/2021.01.15.426911>
17. Chang X, Sousa Augusto G, Liu X, Kundig TM, Vogel M, Mohsen MO, Bachmann MF. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection but recognition of mutant viruses is up to 10-fold reduced. 2021. *bioRxiv* [internet]. Available from: <https://doi.org/10.1101/2021.03.13.435222>
18. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, PVI Study GroupI, Krammer F. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. 2021. *medRxiv* [internet]. Available from: <https://doi.org/10.1101/2021.01.26.21250543>
19. Cheng MH, Krieger JM, Kaynak B, Arditi M, Bahar I. Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment. *bioRxiv* 2021. Available from: <https://doi.org/10.1101/2021.01.10.426143>
20. Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. *Cell*.

2021;184(9):2384-2393.e12. doi:10.1016/j.cell.2021.03.036

21. Yang Q, Hughes TA, Kelkar A, et al. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. *eLife*, 2020; (published online Oct 26) Doi: <https://doi.org/10.7554/eLife.61552>
22. Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. *bioRxiv*. Available from: <https://doi.org/10.1101/2021.04.22.440932>